Matthew Roden

Matthew Roden is President and Chief Executive Officer at Aktis Oncology, and a member of the Aktis Board of Directors. Matt is also an Executive Partner at MPM Capital, serves as Chairman of Turmeric Acquisition Corporation, and is on the Boards of Directors of iTeos Therapeutics and NextPoint Therapeutics. Matt’s career has spanned senior leadership roles in the biopharma industry, the healthcare equity capital markets, and in basic science as an immunologist and structural biologist.

Prior to Aktis Oncology and MPM, Matt was a senior leader at Bristol Myers Squibb, serving as SVP and Head of Enterprise Strategy, as Head of Strategic Corporate Development, accountable for mergers and acquisitions, and as Head of Global BD Assessment, leading business development search and evaluation activities for all therapeutic categories. Matt served on the R&D Leadership Team representing External Innovation and led teams on over 100 business development transactions cumulatively valued at over $125 billion. Prior to his corporate leadership career, Matt was a leading equity research analyst covering the biotechnology sector globally at UBS and J.P. Morgan.

He holds a PhD from the Albert Einstein College of Medicine and was a pre-doctoral fellow at the National Cancer Institute. In his free time, Matt enjoys tackling home improvement projects and spending time with his family sailing or on the ski slopes.